Flibanserin Versus Placebo in Premenopausal Women With HSDD
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month
treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women.
To evaluate safety and tolerability of flibanserin in such patients.